trial

Effect of Food and Age on the Pharmacokinetics of LY03017

NCTId NCT06793995
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Not Yet Recruiting
Enrollment 26 (estimated)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2025-10-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Not Yet Recruiting
Enrollment
26 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2025-02
Primary completion
2025-10-31
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
LY03017

Sponsors

Luye Pharma Group Ltd.Lead Sponsor

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
26
Phase
PHASE1
Primary Completion Date
2025-10-31
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
LY03017
drug
lead_sponsor
Luye Pharma Group Ltd.
company
indication
Alzheimer's Disease Psychosis
indication
Negative Symptoms of Schizophrenia
indication
Parkinson Disease Psychosis
indication